


Multidrug resistant TB (MDR-TB) and COVID19

Lockdown and COVID-19

Nearly **400,000** drug-resistant patients at risk

3 billion + people in almost **70** countries/territories


Asked to stay at home



of the world's population

The highest MDR-TB burden countries

- China
- India
- Indonesia
- South Africa
- Peru
- Kenya
- Russian Federation
- Thailand
- Ukraine
- Peru



of all people with DR TB (300,000 people) caught in lock-down

Key Messages

for high MDR-TB burden countries

01




Ensure ongoing services continue

02



Keep enough medication in stock

03




Continue testing for TB, also DST

04




Run TB & COVID tests in parallel to each other

05



Switch to all-oral regimens

06



Be aware of disruption of drug supplies*

07



Advocate to resume production**

* Since oral regimens will require second-line drugs like Bedaquiline (BDQ), and since India who is producing the drugs, is in an extended lockdown, the whole world needs to worry about disruption of drug supply and shortages in the coming months

**Countries could advocate with the Indian government to resume production soon and give priority to TB medication.

SUPPORTING DR-TB PATIENTS IN TIME OF COVID-19



Regular follow-up visits to a doctor

Ensure patients feel comfortable and confident about the treatment



URGENT ADVICE




Use the shorter oral DR-TB treatment

Give patients several months' supply to self-administer with support of video/online counselling



Interruptions

of ongoing DR TB treatment in COVID-19 pandemic and lockdown



This briefing was adapted especially for the Global TB Caucus from the work of Petra Heitkamp and Professor Madhukar Pai, MD, PhD, FCAHS, Canada Research Chair in Epidemiology & Global Health, Director, McGill Global Health Programs, Director, McGill International TB Centre. Many thanks to them both.